Opimend

Opimend is a clinical-stage biopharmaceutical company focused on developing novel treatments for Central Nervous System (CNS) disorders, specifically targeting addiction and Opioid Use Disorder (OUD). The company's lead program, OPM-101, is a highly selective dopamine D3 receptor antagonist designed to reduce drug-seeking behavior and prevent relapse by modulating the brain's reward circuitry. Unlike traditional medication-assisted treatments that rely on opioid agonists or antagonists, Opimend's approach offers a non-addictive, non-opioid alternative for long-term recovery. The company leverages deep expertise in neuroscience and addiction medicine to address the critical public health crisis of substance abuse. Opimend is headquartered in Gainesville, Florida, and maintains strong ties to academic research institutions.